This company is no longer active
C6O Stock Overview
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Clovis Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.023 |
| 52 Week High | €2.46 |
| 52 Week Low | €0.01 |
| Beta | 0.66 |
| 1 Month Change | 130.00% |
| 3 Month Change | -16.06% |
| 1 Year Change | -99.07% |
| 3 Year Change | -99.60% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| C6O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 53.3% | 1.8% | 2.5% |
| 1Y | -99.1% | -13.8% | 13.4% |
Return vs Industry: C6O underperformed the German Biotechs industry which returned -6.5% over the past year.
Return vs Market: C6O underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| C6O volatility | |
|---|---|
| C6O Average Weekly Movement | 104.6% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: C6O's share price has been volatile over the past 3 months.
Volatility Over Time: C6O's weekly volatility has increased from 91% to 105% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clovis Oncology, Inc. Fundamentals Summary
| C6O fundamental statistics | |
|---|---|
| Market cap | €2.18m |
| Earnings (TTM) | -€226.19m |
| Revenue (TTM) | €119.44m |
0.0x
P/S Ratio0.0x
P/E RatioIs C6O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C6O income statement (TTM) | |
|---|---|
| Revenue | US$133.02m |
| Cost of Revenue | US$31.59m |
| Gross Profit | US$101.43m |
| Other Expenses | US$353.33m |
| Earnings | -US$251.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 76.25% |
| Net Profit Margin | -189.37% |
| Debt/Equity Ratio | -158.0% |
How did C6O perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/12 13:40 |
| End of Day Share Price | 2023/07/12 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clovis Oncology, Inc. is covered by 18 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Alethia Young | Credit Suisse |
| Steven Breazzano | Evercore ISI |